Der Ultimative Calyptemotivationsthread

 

passiert heute erstmal garnichts(Tendenz eher Richtung Süden,2-3 Cents)!
Sollte der Conf.Call nach Börsenschluss so ausfallen,wie wir uns das wünschen,
dann könnte es am Freitag Richtung Norden gehen!
Wollen wir das Beste hoffen.
Bin mal gespannt ob meine Aussage zutrifft.
Oder ist jemand anderer Meinung?

Grüße reliably  

einsetzt. Glaub ich nicht nach den Zahlen die kommen. Glaube aber auch nicht, daß es nach unten geht. Nen Plus von 5-10 % morgen währe auch net, aber noch lange nicht genug. @ Lucky, du siehst ich werde etwas vorsichtiger (und wtten um Calyaktien tue ich auch net mehr,zu wertvoll irgendwann) löl.  

am Donnerstag 22.Juni 2004 10.00 a.m.
findet die jährliche Hauptversammlung
von Calypte statt!  

vielleicht interessiert er euch


QUARTALSZAHLEN HEUTE ABEND...........

Ich habe vor ein paar Wochen einen interessanten Aspekt in Calypte`s Quartalsberichten analysiert.

Naemlich habe ich mir die Inventory zahlen angeschaut.
So ist mir aufgefallen das die Inventory zahlen der 1) Rohprodukte, 2)Produkte in Produktion 3) Fertigprodukte zum Quartalsende in Relation mit den Umsatzzahlen des darauffolgeden Quartals.
Die Analyse ging bis zurueck ins Jahr 1996

Dabei wurde eins klar, das die Inventory Zahlen definitiv ein gewisser Prognose faktor fuer die darauffolgenden Umsatzzahlen sind. Macht ja auch Sinn.

1.) Naemlich: Wenn ich Produkt fuer 2 MIO USD zum Quartalsende in Produktion hab heisst das auf deutsche " Grosse Auftraege in der Pipeline" schliesslich produziere ich ja nicht nach Lust und Laune.

Ich bin bei der Analyse zu folgendem Ergebniss gekommen: Sowohl bei Rohprodukte, Produkte in Produktion hatte Calypte zum ende des 4. Q 2003 die Hoechsten Bestaende in der Firmengeschichte ! Und das soll was heissen meine Herren.

Dies reiht sich auch schoen ein mit dem Fakt, das dieser " Inventory-Indikator" wie ich Taufe, in den vergangenen 7 Quartalen, parrallel mit den Umsatzzahlen Quartal fuer Quartal angestiegen ist.

Weiteres ergebnis der Analyse war, das der Inventory-Indikator den groessten Sprung in der geschichte gemacht hat. Das heisst es ist sehr warscheinlich das die Umsatzzahlen auch einen grossen Sprung fuer das 1Q04 machen werden!
Das heisst im Fazit, der Umsatzwachstum den wir bei Calypte in den letzten 7Q gesehen haben, zugegebenermassen von einem sehr geringem ausgangepunkt her (Umsatzeinbruch nach initial Winddown plan of operations). Das sich dieses Wachstum im 1Q4 und spaetestens im 2Q4 noch acceleriert!

Ich warte mit spannung auf die Zahlen!
Was auch auffaellt, ist das die Quartalszahlen mit 13. Mai so spaet wie noch nie in der Firmengeschichte veroeffentlicht werden. Das heisst: DIE JUNGS HABEN ALLE HAENDE VOLL ZU TUN MIT DER BEARBEITUNG VON AUFTRAEGEN.



Grüße wasträ
 

mfg istvan4


Calypte Enters Into Memorandum of Understanding with Beijing Tiantan Biological Products
Construction on Chinese Manufacturing Facility Underway ALAMEDA, Calif. - PRNewswire-FirstCall - May 13
ALAMEDA, Calif., May 13 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it is has selected Beijing Tiantan Biological Products Co., Ltd. ("BTBP") as its manufacturing partner in China. Under a memorandum of understanding, the parties expect to share technology and equipment to produce Calypte's Rapid HIV-1/2 Antibody Tests in China.

Calypte shall be responsible for supplying technology, manufacturing and quality control equipment and expertise, technical assistance and technical support, while BTBP shall supply the manufacturing facilities where the HIV rapid tests will be produced. Calypte will be in charge of day-to-day operations.

"We are very pleased that this memorandum of understanding whereby BTBP established the long-term cooperation relationship with Calypte and the new cooperation company will manufacture Calypte's HIV rapid products, as BTBP sees a great market potential for Calypte's rapid HIV-1/2 antibody tests in the People's Republic of China, as well as other parts of the world," said Mr. Ni Daoming, BTBP's Board Chairman.

"Our relationship with BTBP is expected to greatly accelerate our entry into the Chinese market," said Dr. J. Richard George, President and CEO of Calypte. "BTBP is one of the leading Chinese companies in the field of biological products and has a vast amount of experience in building and operating Good Manufacturing Practices (GMP) compliant facilities and obtaining regulatory approvals. We will draw upon their experience in these vital areas.

"BTBP, acting on good faith that this memorandum of understanding will lead to a definitive agreement, has met with our technical personnel, jointly defined the needs of the facility and has begun construction of the manufacturing site", Dr. George continued. "This cooperation will enable us to stay on a fast-track by continuing facility construction during the negotiations of a final agreement."

About BTBP:

Beijing Tiantan Biological Products Co. Ltd. is a biotech company listed on the Shanghai Stock Exchange (601161.SS) with a current market capitalization in excess of $300 million (US). The company manufactures multiple vaccines for both viral and bacterial infections. BTBP is the Special Vehicle Company approved for listing on the Shanghai Stock Exchange; the parent company is National Vaccine & Serum Institute who currently owns over 66% after two private placements of the BTBP's shares, including 25 million public shares issued in 2003.

 

NEWS!! Calypte Enters Into Memorandum of Understanding with Beijing Tiantan Biological Products
PR Newswire - May 13, 2004 08:32

Construction on Chinese Manufacturing Facility Underway

ALAMEDA, Calif., May 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it is has selected Beijing Tiantan Biological Products Co., Ltd. ("BTBP") as its manufacturing partner in China. Under a memorandum of understanding, the parties expect to share technology and equipment to produce Calypte's Rapid HIV-1/2 Antibody Tests in China.

Calypte shall be responsible for supplying technology, manufacturing and quality control equipment and expertise, technical assistance and technical support, while BTBP shall supply the manufacturing facilities where the HIV rapid tests will be produced. Calypte will be in charge of day-to-day operations.

"We are very pleased that this memorandum of understanding whereby BTBP established the long-term cooperation relationship with Calypte and the new cooperation company will manufacture Calypte's HIV rapid products, as BTBP sees a great market potential for Calypte's rapid HIV-1/2 antibody tests in the People's Republic of China, as well as other parts of the world," said Mr. Ni Daoming, BTBP's Board Chairman.

"Our relationship with BTBP is expected to greatly accelerate our entry into the Chinese market," said Dr. J. Richard George, President and CEO of Calypte. "BTBP is one of the leading Chinese companies in the field of biological products and has a vast amount of experience in building and operating Good Manufacturing Practices (GMP) compliant facilities and obtaining regulatory approvals. We will draw upon their experience in these vital areas.

"BTBP, acting on good faith that this memorandum of understanding will lead to a definitive agreement, has met with our technical personnel, jointly defined the needs of the facility and has begun construction of the manufacturing site", Dr. George continued. "This cooperation will enable us to stay on a fast-track by continuing facility construction during the negotiations of a final agreement."

About BTBP:

Beijing Tiantan Biological Products Co. Ltd. is a biotech company listed on the Shanghai Stock Exchange (601161.SS) with a current market capitalization in excess of $300 million (US). The company manufactures multiple vaccines for both viral and bacterial infections. BTBP is the Special Vehicle Company approved for listing on the Shanghai Stock Exchange; the parent company is National Vaccine & Serum Institute who currently owns over 66% after two private placements of the BTBP's shares, including 25 million public shares issued in 2003.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV- 1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

Company Contact: Investor Relations Contact:
Dr. J. Richard George Tim Clemensen
President and CEO Rubenstein Public Relations
(510) 749-5100 Phone: 212-843-9337
email:rgeorge@calypte.com Email:tclemensen@rubensteinir.com

SOURCE Calypte Biomedical Corporation

Dr. J. Richard George, President and CEO, Calypte Biomedical
Corporation, +1-510-749-5100, rgeorge@calypte.com; or Tim Clemensen,
Rubenstein Public Relations, +1-212-843-9337, tclemensen@rubensteinir.com, for
Calypte
 

 

fassen die news.währe ich sehr dankbar für. danke @wasserträger für den beitrag.find ich echt ne gute beobachtung.  

hat in China einen Partner gefunden,der die Herstellung
der Caly -Produkte übernimmt!
Nachfolgend Alta vista Übersetzung:

ALAMEDA, Calif., Mai 13, 2004 /PRNewswire-FirstCall über COMTEX/ -- Calypte Biomedical Corporation (OTC Anschlagbrett: CYPT), ein Entwickler, ein Hersteller und ein Marketingspezialist HIV der Diagnosetests, verkündeten heute, daß er ist hat vorgewählt Beijing Tiantan biologische Produkte Co., Ltd. ("BTBP") als sein Herstellung Partner in China. Unter einer Vereinbarung, erwarten die Beteiligten, Technologie und Ausrüstung zu teilen, um Calypte's schnelle Tests des Antikörper-HIV-1/2 in China zu produzieren. Calypte ist für das Liefern von von Technologie, von von Herstellung und von von von von Qualitätskontrolleausrüstung und -sachkenntnis, von von technischer Unterstützung und von von technischer Unterstützung verantwortlich, während BTBP die Produktionsanlagen liefert, in denen die HIV schnellen Tests produziert werden. Calypte ist verantwortlich für Alltagsbetriebe. "We sind sehr erfreut, das diese Vereinbarung, hingegen BTBP das langfristige Mitarbeit-Verhältnis zu Calypte aufbaute und die neue Mitarbeitfirma Calypte's HIV schnelle Produkte herstellt, wie BTBP ein großes Marktpotential für Calypte's schnelle Tests des Antikörpers HIV-1/2 in der People's Republik von China, sowie andere Teile der Welt, " sieht; besagter Herr Ni Daoming, BTBP's Brett-Vorsitzender. "Our Verhältnis zu BTBP wird beschleunigen groß unsere Eintragung in den chinesischen Markt, " erwartet; besagter Dr. J. Richard George, Präsident und CEO von Calypte. "BTBP ist eine der führenden chinesischen Firmen auf dem Gebiet der biologischen Produkte und hat eine beträchtliche Menge Erfahrung im Gebäude und in funktionierendem gutem gefälligem Service der Herstellungsmethoden (GMP) und im Erreichen von von Genehmigungen durch die zuständige Aufsichtsbehörde. Wir zeichnen nach ihrer Erfahrung in diesen lebenswichtigen Bereichen. "BTBP, auf gutem Glauben, den diese Vereinbarung zu einer endgültigen Vereinbarung führt, getroffen unser technisches Personal hat, gemeinsam definiert fungierend den Notwendigkeiten des Service und hat angefangen Aufbau des Herstellung site", Dr. George fuhr fort. "This Mitarbeit ermöglicht uns, auf einer Schnellschiene zu bleiben, indem sie Service-Aufbau während der Vermittlungen eines abschließenden agreement." fortsetzt;
 

 

plus 20 - 25 % erwarte ich persönlich heute  

die zahlen werden schlecht sein das ist klar, aber die zukunft kann uns sehr viel geld bringen. der zug beginnt zu rollen.....  

nachrichten.geht aufwärts. caly ist auf dem richtigen weg. langsam.der durchbruch könnte kommen dieses jahr,sollte kommen.  

 

hen, Caly Ole

Gruß Werweiß  

schaffen das noch auf gehts Caly jeeeeeeehaaaaaaaaaaaaa  

wer von Euch hat da gerade die 23400 Stück
in Frankfurt geordert?  

*heiligenscheintastesuch*

mfg kram  

mit den Quartalszahlen!  

Calypte Announces First Quarter Financial Results

ALAMEDA, Calif., May 13 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a developer, manufacturer and marketer of HIV diagnostic tests, today announced financial results for the first quarter ended March 31, 2004. Revenues for the quarter totaled $971,000 compared with $784,000 for the comparable period in 2003, an increase of 24% from the same quarter a year ago.

The net loss attributable to common stockholders for the quarter was $4.04 million or $0.03 per common share, compared with a net loss attributable to common stockholders of $6.37 million or $1.11 per common share, for the three months ended March 31, 2003. The net loss for the first quarter of 2004 included $701,000 in non-cash charges that were related to the grants of common stock and options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments. During the quarter ended March 31, 2003, non-cash charges totaled $3,587,000 related to the same types of expenses.

"Calypte is becoming a more efficient and streamlined company," stated Tony Cataldo, Calypte's executive chairman. "As the international demand for alternative testing grows, as well as the need to constantly evaluate the success of HIV intervention programs using novel approaches such as the HIV incidence tests that we are working on with the CDC (Centers for Disease Control and Prevention), we believe that the company is positioned properly to take a lead in the field of diagnostic testing."

Recent Highlights:

Following are Calypte's most significant milestones since the last quarterly release:

* The Marr Group through its subsidiaries continues to work with the Company to expand the business in China. In this regard, based on a memorandum of understanding with Beijing Tiantan Biological Products Co., Inc. ("BTBP"), construction is underway on a Chinese manufacturing facility. BTBP is a biotech company listed on the Shanghai Stock Exchange (601161.SS). BTBP is the Special Vehicle Company approved for listing on the Shanghai Stock Exchange; the parent company is National Vaccine & Serum Institute who currently owns over 66 % after two private placements of the BTBP's shares, including 25 million public shares issued in 2003. BTBP manufactures multiple vaccines for both viral and bacterial infections. BTBP has experience in operating life science quality manufacturing facilities and obtaining regulatory approvals for its products.

* Calypte is committed to and focused on the introduction of one or more rapid HIV-1 and HIV-2 diagnostic tests in markets including Africa, Asia, and Russia. The Company signed a manufacturing agreement with Pacific Biotech Co. Ltd. in Thailand and will transfer the first of its products, a rapid HIV-1 / 2 antibody test for blood, serum, and plasma to this facility in the upcoming weeks. Product is expected to be available for sale in the second half of this year.

* Calypte continues international field trials of its developmental stage urine and blood rapid tests in Thailand, and is adding a trial site in China shortly. The Company will have three active trial sites that will enable it to accelerate the testing process. Given the similarities in manufacturing techniques, the Company expects to achieve a quick transfer of its urine product(s) into production once it is satisfied with the results coming from these field trials.

* The Company initiated a CRADA (Cooperative Research and Development Agreement) with the CDC that calls for the development of a rapid blood-based HIV antibody product in conjunction with the CDC. The proposed product will not only be diagnostic but will also provide a reaction line to measure incidence, which is a measure of whether an HIV infection occurred in the recent or remote past. Research and development is under way. In addition, the manufacturing of a laboratory-based ELISA incidence test that has been undertaken in the past by the CDC is being transferred from the CDC to Calypte's Rockville, Maryland facility, thereby increasing the utilization and efficiency of Calypte's operation there. Further, because this incidence test is not for diagnostic purposes, it is expected to have a short regulatory process and quick time to market in the second half of 2004. The Company is already receiving inquiries regarding the availability of our product for sale.

* The consolidation of Calypte's domestic manufacturing operations in Rockville is progressing according to schedule and, when completed, is expected to eliminate approximately $1 million of annual expense, including approximately $500,000 in annual occupancy costs, and create a more efficient and cost effective manufacturing structure. The Company expects to exit its Alameda manufacturing facility at the end of June, and has largely completed the inventory build-up necessary for the transition.

Calypte will hold a conference call Thursday, May 13 at 5:00 p.m. (EDT), 2:00 p.m. (PDT). Investors can access the call from the investor section of the Calypte web site, at www.calypte.com. Investors in the U.S. and Canada interested in participating in the conference call may dial 800-599-9795 and reference the Calypte Biomedical call. International investors may dial 617-786-2905. Calypte recommends dialing into the call approximately 10 minutes prior to the scheduled start time. The webcast will be available until June 12, 2004. A telephone replay will be available through June 12, 2004 by calling 888-286-8010. International callers should dial 617-801-6888 for the replay. The replay confirmation code is 42377175.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV- 1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

Investor Relations Contact:
Tim Clemensen
212-843-9337
email: tclemensen@rubensteinir.com


              CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES

                   CONSOLIDATED STATEMENTS OF OPERATIONS
                   (in thousands, except per share data)
                                 Unaudited

                                                       Three Months Ended
                                                            March 31,
                                                     2004              2003
    Revenues:
      Product sales                                  $971              $784

      Cost of product sales                         1,980             1,415
        Gross Margin (Loss) on product sales       (1,009)             (631)

    Other operating expenses:
      Research and development costs                  541               314
      Selling, general and administrative costs     2,196             4,009

        Total other operating expenses              2,737             4,323

          Loss from operations                     (3,746)           (4,954)

    Interest income (expense) (primarily
     non-cash for both periods)                      (297)           (1,516)

    Other income (expense)                              5               128

          Loss before income taxes                 (4,038)           (6,342)

    Income taxes                                       (2)               (2)

          Net loss                                 (4,040)           (6,344)

    Less dividends on mandatorily redeemable
     Series A preferred stock                          --               (30)

    Net loss attributable to common stockholders  $(4,040)          $(6,374)

    Net loss per share attributable to
     common stockholders
      (basic and diluted)                          $(0.03)           $(1.11)

    Weighted average shares used to
     compute net loss per share attributable to
      common stockholders
      (basic and diluted)                         136,679             5,755



               CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARY

                      CONSOLIDATED BALANCE SHEET DATA
                               (in thousands)
                                 Unaudited

                                                 March 31,      December 31,
                                                     2004              2003

    Cash and cash equivalents                      $1,656            $5,084
    Working capital                                  (414)            2,865
    Total Assets                                    6,341             9,517
    Convertible notes and debentures,
     net of discount                                  913               868
    Other long term liabilities                       140               157
    Mandatorily redeemable Series A
     preferred stock                                2,726             2,696
    Total stockholders' equity (deficit)           (2,181)              917

SOURCE Calypte Biomedical Corporation
05/13/2004
CONTACT:
Tim Clemensen
+1-212-843-9337, tclemensen@rubensteinir.com
for Calypte Biomedical Corporation
Web site: http://www.calypte.com

 

About Calypte Biomedical Corp. (OTC BB:CYPT.OB)	Other Calls
Calypte Biomedical Corporation develops, manufactures and markets urine-based screening and supplemental tests for the detection of antibodies to the Human Immunodeficiency Virus, Type-1 (HIV-1), the putative cause of Acquired Immunodeficiency Syndrome (AIDS). It has obtained United States Food and Drug Administration (FDA) approval for the marketing and sale of urine-based tests for the detection of antibodies to the HIV-1. In clinical trials using the screening and supplemental tests together, the urine HIV antibody testing algorithm detected the presence of HIV antibodies in urine with 99.7% sensitivity in subjects previously identified as HIV-1 infected through blood-based (serum/plasma) screening tests. More from Reuters: Expanded Business Description
More Info: Quote | Chart | News | Profile | Reports | Research | Insider | Financials

---

 

 

Gruß

leo

 

Auch Grüße an Alle  

sondern lediglich das schon bestehende und eine Beschreibung zu Calypte ! Oder habe ich da was falsch verstanden ?

Grüße  

war bekannt aber ist halt die Zukunft !

Gruß

leo